Erasca, Inc. Stock Price, News & Analysis

Erasca, Inc. (Nasdaq: ERAS) announced a clinical trial collaboration and supply agreement with Pfizer to evaluate ERAS-007, an oral ERK1/2 inhibitor, in combination with the CDK4/6 inhibitor palbociclib for patients with KRAS- and NRAS-mutant colorectal and pancreatic cancers. This study is part of the Phase 1b/2 HERKULES-3 trial, sponsored by Erasca. Approximately 1.8 million cases of colorectal cancer and 0.5 million cases of pancreatic cancer are diagnosed annually, with a significant portion harboring RAS mutations. The combination aims to enhance treatment efficacy and reduce resistance.

Erasca, Inc. (Nasdaq: ERAS) announced initial Phase 1/1b data for its ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601, showcasing safe profiles for potential combination therapies in solid tumors. ERAS-801, a CNS-penetrant EGFR inhibitor, shows enhanced anti-tumor activity over osimertinib in preclinical models. New KRAS G12D inhibitors demonstrate significant tumor growth inhibition. The company will present findings at the 34th EORTC-NCI-AACR Symposium in October 2022, with further data expected in 2023, highlighting ongoing advancements in their oncology pipeline.

Erasca, Inc. (Nasdaq: ERAS), a company dedicated to precision oncology, will participate in the Bank of America Securities Precision Oncology Conference on October 3, 2022, at 3:40 PM ET. CEO Jonathan E. Lim and CFO David M. Chacko will engage in a virtual fireside chat and one-on-one investor meetings. A live webcast will be available, with an archived replay until January 3, 2023. Erasca aims to innovate therapies for RAS/MAPK pathway-driven cancers, leveraging a strong pipeline and expert advisory board to achieve its mission of erasing cancer.

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company, announced its participation in the Morgan Stanley Global Healthcare Conference. On September 14, 2022, at 12:55 PM ET, CEO Jonathan E. Lim, M.D., and CFO David M. Chacko, M.D., will engage in a fireside chat at Sheraton Hotel, New York. They will also conduct one-on-one investor meetings. A live webcast will be available, with an archived replay accessible until December 14, 2022. Erasca is focused on therapies for RAS/MAPK pathway-driven cancers, aiming to develop innovative cancer treatments.

Erasca, a clinical-stage precision oncology company, reported promising Phase 1/1b data for its ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in treating RAS/MAPK-altered solid tumors. The retrospective analysis revealed that 23% of patients with non-CRC solid tumors and 44% of those with BRAF-driven tumors responded to these agents. Both drugs demonstrated favorable safety profiles, supporting their combination in upcoming trials. The initiation of the ERAS-007 plus ERAS-601 MAPKlamp trial is anticipated in the first half of 2023.

Erasca, Inc. (Nasdaq: ERAS) will host a virtual research and development day on September 7, 2022, featuring key opinion leader Dr. David Hong from MD Anderson Cancer Center. The event will present preliminary clinical data for Erasca's lead candidates, the ERK1/2 inhibitor ERAS-007 and the SHP2 inhibitor ERAS-601, targeting advanced solid tumors influenced by the RAS/MAPK pathway. Participants can register online for the event, which will include a live Q&A session.

Erasca, Inc. (Nasdaq: ERAS) has entered a five-year collaboration with The University of Texas MD Anderson Cancer Center to evaluate multiple agents targeting the RAS/MAPK pathway. The partnership's initial focus is on ERAS-007, an ERK1/2 inhibitor, and ERAS-601, a SHP2 inhibitor. These will be combined in the first MAPKlamp approach. Ongoing clinical trials of these agents will target various cancers, including non-small cell lung cancer and gastrointestinal malignancies. The collaboration aims to enhance the clinical development of Erasca's pipeline in addressing significant cancer treatment challenges.

Erasca, Inc. (Nasdaq: ERAS) reported Q2 2022 financial results, showcasing a cash reserve of $391 million. The company is advancing its clinical programs, expecting initial data for ERAS-007 and ERAS-601 by H2 2022. Notable collaborations include partnerships with Eli Lilly and Harvard Medical School to enhance ERAS-007 and ERAS-601's potential. R&D expenses rose to $27.5 million, driven by clinical trials, while G&A expenses increased to $8.4 million. The net loss for the quarter stands at $35.6 million, or $(0.30) per share.

Erasca has entered a clinical trial collaboration with Eli Lilly to evaluate ERAS-601, a selective SHP2 inhibitor, in the FLAGSHP-1 trial. This Phase 1/1b trial will assess ERAS-601 combined with Lilly's cetuximab for treating triple wildtype metastatic colorectal cancer and HPV-negative advanced head and neck squamous cell carcinoma. Lilly will provide cetuximab at no cost. The collaboration aims to enhance treatment responses and delay resistance onset in RAS/MAPK driven cancers, addressing significant market needs given the rising case numbers of these malignancies.